A vaccine is not too far for COVID-19.

Shailesh Kumar Patel,D Katterine Bonilla-Aldana,Mamta Pathak,Yashpal Singh Malik,Alfonso J Rodriguez-Morales,Mohd. Iqbal Yatoo,Ranjit Sah,Khan Sharun,Ruchi Tiwari,Kuldeep Dhama,Ali A Rabaan

doi:10.3855/jidc.12744

Abstract

N/A

Highlights

Over the last months and weeks of the pandemic of the Coronavirus Disease 2019 (COVID-19) (January-May 2020) caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there has been a significant hope for the development of vaccines against this emerging coronavirus
The structural proteins of SARS-CoV-2 include envelope (E), membrane (M), nucleocapsid (N), and spike (S) protein, which are being investigated as target antigens for vaccine development [10]
In this context, neutralizing antibodies were mainly reported to be directed against the S protein of the earlier zoonotic CoVs as it is the major structural protein can be targeted for the development of a vaccine against the SARS-CoV-2

Summary

Introduction

Over the last months and weeks of the pandemic of the Coronavirus Disease 2019 (COVID-19) (January-May 2020) caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there has been a significant hope for the development of vaccines against this emerging coronavirus. Every aspect of SARS-CoV-2, its structural and non-structural proteins, genetic material, or the disease pathogenesis, are being explored for devising effective vaccines. A thorough understanding of the antigenic structures of SARS-CoV-2 is necessary for the development of vaccine [10].

Results

Conclusion